NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Clinical trials for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new NON-SQUAMOUS NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
BioNTech's RNA cancer therapy trial halted early
Disease control TerminatedThis study tested an experimental RNA-based therapy called BNT142 in people with advanced solid tumors that have a specific protein called CLDN6. The goal was to see if it was safe and could shrink tumors. However, the trial was terminated early, so we don't have clear answers ab…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Cancer drug trial halted midway: what happened?
Disease control TerminatedThis study tested an experimental drug called VLS-101 in 102 people with advanced solid tumors, including breast, lung, ovarian, stomach, and pancreatic cancers that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors. However, the t…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Early cancer drug trial halted after just 3 patients
Disease control TerminatedThis early-stage study tested a new drug called AMG 794 in adults with advanced lung, ovarian, or other solid tumors that have a specific protein (claudin 6). The main goals were to check safety and find the right dose. However, the study was stopped early after only 3 people enr…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Lung cancer drug cocktail trial ends early – what we know
Disease control TerminatedThis phase 3 trial tested a combination of three drugs—camrelizumab (an immunotherapy), famitinib (a targeted therapy), and standard chemotherapy—in 48 people with advanced non-squamous non-small-cell lung cancer that did not have certain genetic changes. The study aimed to see i…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC